Newsbenzinga
Sanofi Secures EU Approval For Cenrifki As First Disability-Targeting Medicine For Secondary Progressive Multiple Sclerosis Without Relapses
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…